We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Technopath Showcases Third Party Quality Controls and Quality Control Software Solutions at AACC 2021

By LabMedica International staff writers
Posted on 28 Sep 2021
Print article
Image: Multichem ID-Covid 19 Quality Controls (Photo courtesy of Technopath Clinical Diagnostics)
Image: Multichem ID-Covid 19 Quality Controls (Photo courtesy of Technopath Clinical Diagnostics)

Technopath Clinical Diagnostics (Tipperary, Ireland) showcased its third party quality controls and quality control software solutions at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo held at the Georgia World Congress Center in Atlanta, September 26-30.

The event allowed more than 400 exhibiting companies to showcase the latest product innovations, emerging technologies, and research, and provided the opportunity to browse exhibitors in person for the solutions to lab related needs.

Technopath is one of the largest manufacturers of liquid-ready Quality Control globally in compliance with the highest quality standards. At AACC 2021, the company highlighted Multichem, its class leading third party consolidated Quality Control product range which incorporates a greater number of analytes to enable extensive test menu and control product consolidation. The Multichem IA+ control, for example, allows consolidation of the company’s competitors’ immunoassay, cardiac marker, tumor marker and specialty immunoassay controls into one control. This consolidation allows laboratories to simplify their inventory, reduce costs and improve efficiencies.

For instance, Multichem ID-COVID19 controls are the essential independent quality controls designed to test the precision of assays for antibodies IgG and IgM to SARS-CoV-2, to allow clinical laboratories to release patient results with confidence. The company also exhibited its flagship chemistry product, Multichem S Plus (S for Serum) which consolidates over 100 analytes in to a single product. Also on display was Technopath's leading diabetes product, Multichem A1c, which is a third party QC for hemoglobin A1c. Other products displayed at the event included flagship immunoassay product is Multichem IA Plus which consolidates over 90 analytes in to a single product and can replace up to four competitor products in the lab; and its leading urine chemistry control is Multichem U which provides a single product to cover the majority of standard urine chemistry assays, including Microalbumin, which some competitors provide a separate QC product for.

Alomgside its Multichem quality control product range, Technopath also demonstrated its IAMQC Software which provides laboratory managers and technologists with a range of QC software tools to analyze their QC results in real-time. IAMQC Software tools allow users to automate, centralize, standardize and improve QC processes in a laboratory setting. A combination of modules satisfies the varying levels of QC requirements in individual laboratories and are easily tailored to meet different QC management expectations.

Related Links:
Technopath Clinical Diagnostics

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test
New
Amoebiasis Test
ELI.H.A Amoeba

Print article
ADLM

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.